Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

593
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
593
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

343
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
343
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

2.1K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
2.1K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.5K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

557
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
557
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

189
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
189

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low dose slow and ultraslow thrombolytic therapy for patients with prosthetic valve thrombosis: a pharmacist-led protocol experience from a Middle Eastern quaternary care center.

Frontiers in cardiovascular medicine·2026
Same author

Regional Disparities and Unmet Needs in Long-Term Durable Left Ventricular Assist Device Support Across Europe.

Artificial organs·2026
Same author

Refining Atrial Shunt Therapy for Heart Failure With Preserved Ejection Fraction: Lessons From Pivotal Randomized Trials and Emerging Directions.

Journal of cardiac failure·2025
Same author

Pumping up Survival: Strategy of LVAD First in Younger Patients for Net Prolongation of Life.

Journal of cardiac failure·2025
Same author

The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology.

American journal of preventive cardiology·2025
Same author

The iron woman: a case report of contemporary cardiac support.

European heart journal. Case reports·2025

Related Experiment Video

Updated: Dec 13, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K

Heart failure and COVID-19.

Feras Bader1,2, Yosef Manla3, Bassam Atallah4

  • 1Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, PO Box 112412, Abu Dhabi, United Arab Emirates. baderf@clevelandclinicabudhabi.ae.

Heart Failure Reviews
|July 29, 2020
PubMed
Summary
This summary is machine-generated.

COVID-19 can complicate heart failure presentation and management. Understanding cardiac implications and medication interactions is crucial for optimal care, especially for advanced heart failure patients.

Keywords:
COVID-19Cardiac biomarkersHeart failureHemodynamics

More Related Videos

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice
08:21

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Published on: June 15, 2020

4.7K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.0K

Related Experiment Videos

Last Updated: Dec 13, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.1K
Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice
08:21

Biventricular Assessment of Cardiac Function and Pressure-Volume Loops by Closed-Chest Catheterization in Mice

Published on: June 15, 2020

4.7K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

25.0K

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Heart failure (HF) is frequently observed in COVID-19 patients, presenting unique management challenges.
  • COVID-19 can exacerbate existing HF or precipitate new-onset HF due to various mechanisms.
  • Understanding hemodynamic and diagnostic implications is vital for patient triage and care.

Purpose of the Study:

  • To elucidate the complex interplay between COVID-19 and heart failure.
  • To provide guidance on managing HF patients during the COVID-19 pandemic.
  • To clarify the role of cardiac biomarkers and cytokine storm in COVID-19-associated HF.

Main Methods:

  • Review of current literature on COVID-19 and heart failure.
  • Analysis of mechanisms leading to cardiac injury in COVID-19.
  • Evaluation of drug interactions between HF medications and COVID-19 treatments.

Main Results:

  • Abnormal cardiac biomarkers in COVID-19 result from viral mechanisms, direct injury, thrombosis, and stress cardiomyopathy.
  • Cytokine storm significantly contributes to cardiac manifestations.
  • Guideline-directed HF therapy should continue based on clinical tolerance, not theoretical concerns.

Conclusions:

  • Optimal management requires understanding the bidirectional relationship between HF and COVID-19, including medication interactions.
  • Interruption of guideline-directed medical therapy for HF is generally not recommended without clinical indication.
  • Advanced HF patients, including heart transplant recipients, benefit from specialized team involvement during COVID-19 infection.